Gyre Therapeutics (GYRE) Income towards Parent Company (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Income towards Parent Company of -$9.9 million for Q1 2026, down 364.01% year-over-year from $3.7 million in Q1 2025, and down 6339.24% quarter-over-quarter from $158000.0 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Income towards Parent Company (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Income towards Parent Company for 17 consecutive years, with -$9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 364.01% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at -$2.2 million (down 118.71% YoY), while the FY2025 annual figure was $11.4 million, down 36.28% from the prior year.
- Income towards Parent Company eased to -$9.9 million in Q1 2026 per GYRE's latest filing, from $158000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $51.6 million in Q2 2022 and bottomed at -$101.0 million in Q4 2023.
- Historically, Income towards Parent Company has averaged -$3.7 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 325.48% — and 2026, when it plunged 364.01%.
- Gyre Therapeutics' Income towards Parent Company stood at -$28.8 million in 2022, then slumped by 250.76% to -$101.0 million in 2023, then jumped by 100.56% to $569000.0 in 2024, then plunged by 72.23% to $158000.0 in 2025, then sank by 6339.24% to -$9.9 million in 2026.
- Business Quant data shows GYRE's Income towards Parent Company at -$9.9 million in Q1 2026, $158000.0 in Q4 2025, and $5.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.27 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | -433,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -101.81 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -28.79 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.24 Mn |